IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0226552.html
   My bibliography  Save this article

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia

Author

Listed:
  • Kibum Kim
  • Gwendolyn A McMillin
  • Philip S Bernard
  • Srinivas Tantravahi
  • Brandon S Walker
  • Robert L Schmidt

Abstract

Background: Imatinib mesylate (IM) is a first-line treatment option for patients with chronic myeloid leukemia (CML). Patients who fail or are intolerant to IM therapy are treated with more expensive second and third-generation tyrosine kinase inhibitors. Patients show wide variation in trough concentrations in response to standard dosing. Thus, many patients receive subtherapeutic or supratherapeutic doses. Therapeutic drug monitoring (TDM) may improve dose management that, in turn, may reduce costs and improve outcomes. However, TDM also adds to the cost of patient care. The objective of this study was to determine the cost-effectiveness of TDM for generic IM therapy. Methods: We developed a microsimulation model for the trough plasma concentration of IM which is related to a cytogenetic or molecular response. We compared two cohorts: one with TDM and one without TDM (NTDM). The lifetime incremental cost-effectiveness ratio (ICER) was calculated using quality-adjusted life years (QALYs) as the effectiveness measure. One-way and probabilistic sensitivity analyses were performed. Results: The lifetime cost and QALY of treatment with TDM were $2,137K [95% Ci: 2,079K; 2,174K] and 12.37 [95% CI: 12.07; 12.55], respectively. The cost and QALY of NTDM were $2,132K [95% CI: 2,091K; 2,197K] and 12.23 [95% CI: 11.96; 12.50], respectively. The incremental cost and QALY for TDM relative to NTDM was $4,417 [95% CI: -52,582; 32,097]) and 0.15 [95% CI: -0.13; 0.28]. The ICER for TDM relative to NTDM was $30,450/QALY. Probabilistic sensitivity analysis showed that TDM was cost-effective relative to NTDM in 90% of the tested scenarios at a willingness-to-pay threshold of $100,000/QALY. Conclusions: Although the impact of TDM is modest, the cost-effectiveness over a lifetime horizon (societal perspective, ($30,450/QALY) falls within the acceptable range (

Suggested Citation

  • Kibum Kim & Gwendolyn A McMillin & Philip S Bernard & Srinivas Tantravahi & Brandon S Walker & Robert L Schmidt, 2019. "Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia," PLOS ONE, Public Library of Science, vol. 14(12), pages 1-21, December.
    • Handle: RePEc:plo:pone00:0226552
    DOI: 10.1371/journal.pone.0226552
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0226552
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0226552&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0226552?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Dennis G. Fryback & Erik J. Dasbach & Ronald Klein & Barbara E.K. Klein & Norma Dorn & Kathy Peterson & Patrica A. Martin, 1993. "The Beaver Dam Health Outcomes study," Medical Decision Making, , vol. 13(2), pages 89-102, June.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hirsch Ruchlin & Ralph Insinga, 2008. "A Review of Health-Utility Data for Osteoarthritis," PharmacoEconomics, Springer, vol. 26(11), pages 925-935, November.
    2. Michele Kohli & Cheryl Attard & Annette Lam & Daniel Huse & John Cook & Chantal Bourgault & Evo Alemao & Donald Yin & Michael Marentette, 2006. "Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada," PharmacoEconomics, Springer, vol. 24(8), pages 815-830, August.
    3. Louis S. Matza & Katherine J. Kim & Holly Yu & Katherine A. Belden & Antonia F. Chen & Mark Kurd & Bruce Y. Lee & Jason Webb, 2019. "Health state utilities associated with post-surgical Staphylococcus aureus infections," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(6), pages 819-827, August.
    4. William M Reichmann & Jeffrey N Katz & Elena Losina, 2011. "Differences in Self-Reported Health in the Osteoarthritis Initiative (OAI) and Third National Health and Nutrition Examination Survey (NHANES-III)," PLOS ONE, Public Library of Science, vol. 6(2), pages 1-7, February.
    5. Erik Nord & Paul Menzel & Jeff Richardson, 2003. "The value of life: individual preferences and social choice. A comment to Magnus Johannesson," Health Economics, John Wiley & Sons, Ltd., vol. 12(10), pages 873-877, October.
    6. Stavros Petrou & Christine Hockley, 2005. "An investigation into the empirical validity of the EQ‐5D and SF‐6D based on hypothetical preferences in a general population," Health Economics, John Wiley & Sons, Ltd., vol. 14(11), pages 1169-1189, November.
    7. Thi-Phuong-Lan Nguyen & Paul F M Krabbe & Thi-Bach-Yen Nguyen & Catharina C M Schuiling-Veninga & E Pamela Wright & Maarten J Postma, 2015. "Utilities of Patients with Hypertension in Northern Vietnam," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-9, October.
    8. Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
    9. James F Burke & Kenneth M Langa & Rodney A Hayward & Roger L Albin, 2014. "Modeling Test and Treatment Strategies for Presymptomatic Alzheimer Disease," PLOS ONE, Public Library of Science, vol. 9(12), pages 1-20, December.
    10. William Hollingworth & Richard A. Deyo & Sean D. Sullivan & Scott S. Emerson & Darryl T. Gray & Jeffrey G. Jarvik, 2002. "The practicality and validity of directly elicited and SF‐36 derived health state preferences in patients with low back pain," Health Economics, John Wiley & Sons, Ltd., vol. 11(1), pages 71-85, January.
    11. Mengjun Wu & John Brazier & Benjamin Kearns & Clare Relton & Christine Smith & Cindy Cooper, 2015. "Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 16(2), pages 141-151, March.
    12. Joshua T. Cohen & John D. Graham, 2003. "A Revised Economic Analysis of Restrictions on the Use of Cell Phones While Driving," Risk Analysis, John Wiley & Sons, vol. 23(1), pages 5-17, February.
    13. Sherine E. Gabriel & Terry S. Kneeland & L. Joseph Melton & Megan M. Moncur & Bruce Ettinger & Anna N.A. Tosteson, 1999. "Health-related Quality of Life in Economic Evaluations for Osteoporosis," Medical Decision Making, , vol. 19(2), pages 141-148, April.
    14. John Anderson & Robert Kaplan & Christopher Ake, 2004. "Arthritis Impact on U.S. Life Quality: Morbidity and Mortality Effects From National Health Interview Survey Data 1986–1988 and 1994 Using QWBX1 Estimates of Well-Being," Social Indicators Research: An International and Interdisciplinary Journal for Quality-of-Life Measurement, Springer, vol. 69(1), pages 67-91, October.
    15. Daniel Sperber & Alan Shiell & Ken Fyie, 2010. "The cost‐effectiveness of a law banning the use of cellular phones by drivers," Health Economics, John Wiley & Sons, Ltd., vol. 19(10), pages 1212-1225, October.
    16. Trude Arnesen & Mari Trommald, 2005. "Are QALYs based on time trade‐off comparable? – A systematic review of TTO methodologies," Health Economics, John Wiley & Sons, Ltd., vol. 14(1), pages 39-53, January.
    17. Maria Biasutti & Natacha Dufour & Clotilde Ferroud & William Dab & Laura Temime, 2012. "Cost-Effectiveness of Magnetic Resonance Imaging with a New Contrast Agent for the Early Diagnosis of Alzheimer's Disease," PLOS ONE, Public Library of Science, vol. 7(4), pages 1-14, April.
    18. W. Groot & H. M. van den Brink, 2008. "Health-adjusted life expectancy of the British population," Applied Economics, Taylor & Francis Journals, vol. 40(11), pages 1373-1386.
    19. Xiao Zang & Houlin Tang & Jeong Eun Min & Diane Gu & Julio S G Montaner & Zunyou Wu & Bohdan Nosyk, 2016. "Cost-Effectiveness of the ‘One4All’ HIV Linkage Intervention in Guangxi Zhuang Autonomous Region, China," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-17, November.
    20. Costa-Font, Montserrat & Costa-Font, Joan, 2009. "Heterogeneous 'adaptation' and 'income effects' across self-reported health distribution?," Journal of Behavioral and Experimental Economics (formerly The Journal of Socio-Economics), Elsevier, vol. 38(4), pages 574-580, August.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0226552. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.